Plain-English translation of NCT05317455 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 1 research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called to see if it can help your brain work better when your blood sugar drops dangerously low. Many people with type 1 diabetes who experience frequent low blood sugar episodes have trouble thinking clearly during these events. The study will compare the medication to a placebo (a dummy pill) to find out if restoring how your brain uses glucose can help keep your mind sharp when blood sugar is low.
When blood sugar drops very low, your brain struggles to function normally, which can make it hard to think clearly or recognize that you need help. This medication may help restore your brain's ability to use glucose properly during these dangerous moments, potentially preventing confusion and cognitive problems that come with severe low blood sugar.
You likely qualify if…
You likely don't qualify if…
You will take either the test medication or a placebo by mouth, and then your blood sugar will be carefully controlled in the research setting to see how your brain responds during a low blood sugar episode. The study uses a crossover design, meaning you will try both the medication and the placebo at different times so researchers can compare how each affects your thinking and brain function. Throughout the study, your cognitive abilities and brain glucose metabolism will be closely monitored.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Yale University
Enrollment target
~16 participants
Started
May 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alice Hahn
Yale University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.